Introduction | Right Decisions

Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

The prevalence of maternal hyperthyroidism due to Graves’ disease in pregnancy varies from 0.1% to 2.7%. The prevalence of subsequent, transient neonatal Graves’ disease is uncertain, varying from 1.5% to 20% in some studies.

Foetal thyroid development is in progress by week 7 gestation, thyroid hormone synthesis begins in weeks 10-12 and the thyroid is functionally mature by week 25. The causal antibodies in Graves’ disease, thyroid stimulating hormone (TSH) receptor antibodies (TRAb) freely cross the placenta, particularly in the second half of pregnancy thus putting the developing foetus at risk of hyperthyroidism.

Infants with hyperthyroidism may present in utero, usually in the 3rd trimester with signs that include tachycardia, heart failure with non-immune hydrops, IUGR, preterm birth and craniosynostosis.